ATYR news

aTyr Pharma filed an amendment to its certificate of incorporation as part of a reverse stock split effective in roughly two years, which consolidates 40 shares of common stock into one. This move is aimed at meeting the continuous listing requirements of The Nasdaq Stock Market.

aTyr Pharma released an investor presentation outlining advancement of efzofitimod, its tRNA synthetase-derived therapeutic candidate, for pulmonary sarcoidosis and additional indications. The filing demonstrates the company's ongoing clinical development efforts and potential market opportunity in …